Products for Research Use Only

PAK4-IN-5

CAT: 0804-HY-159897Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-159897Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PAK4-IN-5 (Compound 12i) is a PAK4 inhibitor (IC50: 7.68 nM for PAK4, 1872.01 nM for PAK1) . PAK4-IN-5 binds to PAK4 stably via multiple interactions. PAK4-IN-5 inhibits the proliferation and the migratory potential of MDA-MB-231 cells by inhibiting the phosphorylation of PAK4 and LIMK1. PAK4-IN-5 arrests cell cycle in the G0/G1 phase, induces apoptosis and ROS production. LD50: >500 mg/kg for mice (p.o.) [1].
UNSPSC
12352005
Target
Apoptosis; LIM Kinase (LIMK) ; PAK; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pak4-in-5.html
Smiles
CN1CCN(C2=CC=C(C3=CC=C(N=C(C4=CC=C(C(NC5=CC=CC(Cl)=C5)=O)C=C4)N6)C6=C3)C=C2)CC1
Molecular Formula
C31H28ClN5O
Molecular Weight
522.04
References & Citations
[1]Hao S, et al. Design, synthesis and biological evaluation of novel benzimidazole-derived p21-activited kinase 4 (PAK4) inhibitors bearing a 4- (4-methylpiperazin-1-yl) phenyl scaffold as potential antitumor agents. Eur J Med Chem. 2024 Oct 17;280:116971.|[2]Meng FH. Design, synthesis and biological evaluation of novel benzimidazole-derived p21-activited kinase 4 (PAK4) inhibitors bearing a 4- (4-methylpiperazin-1-yl) phenyl scaffold as potential antitumor agents. Eur J Med Chem. 2024 Oct 17;280:116971.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PAK1; PAK4